Wealth Enhancement Trust Services
FATE icon

Wealth Enhancement Trust Services’s Fate Therapeutics FATE Stock Holding History

Wealth Enhancement Trust Services’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-345
Closed -$932 – 1030
2026
Q2 		$932 Buy
+345
New +$638 ﹤0.01% 1145

Other funds holding FATE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wealth Enhancement Trust Services's FATE Position: Q3 2026 in Review

Wealth Enhancement Trust Services sold out of Fate Therapeutics (FATE) in Q3 2026, closing a stake of 345 shares — an estimated $932 sold.

Wealth Enhancement Trust Services first reported a position in FATE in Q2 2026 and held it in 1 quarter. The position peaked at $932 in Q2 2026. 101 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Wealth Enhancement Trust Services reported no remaining Fate Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Trust Services sold 345 Fate Therapeutics shares in Q3 2026, an estimated $932.
  • Wealth Enhancement Trust Services first reported a position in Fate Therapeutics in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Trust Services's Fate Therapeutics position peaked at $932 in Q2 2026.
  • 101 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q3 2026, filed 7 Oct 2026.